Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5:444–70. https://doi.org/10.4239/wjd.v5.i4.444.

Article  PubMed  PubMed Central  Google Scholar 

Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83. https://doi.org/10.1186/s12933-018-0728-6.

Article  PubMed  PubMed Central  Google Scholar 

Cebrián-Cuenca AM, Mata-Cases M, Franch-Nadal J, Mauricio D, Orozco-Beltrán D, Consuegra-Sánchez L. Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population. Eur J Prev Cardiol. 2022;28:e32–4. https://doi.org/10.1093/eurjpc/zwaa073.

Article  PubMed  Google Scholar 

Artime E, Romera I, Díaz-Cerezo S, Delgado E. Epidemiology and economic burden of cardiovascular disease in patients with type 2 diabetes mellitus in Spain: a systematic review. Diabetes Ther. 2021;12:1631–59. https://doi.org/10.1007/s13300-021-01060-8.

Article  PubMed  PubMed Central  Google Scholar 

Reyes-García R, Moreno-Pérez O, Bellido-Castañeda V, Botana López M, Rodríguez-Hervada AD, Fernández-García D. Abordaje integral de las personas con diabetes tipo 2. Área de Conocimiento de Diabetes de la Sociedad Española de Endocrinología y Nutrición. https://www.seen.es; 2023. Accessed 28 Mar 2023.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323. https://doi.org/10.1093/eurheartj/ehz486.

Article  PubMed  Google Scholar 

Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021;9:46–52. https://doi.org/10.1016/S2213-8587(20)30343-0.

Article  CAS  PubMed  Google Scholar 

American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, Benson G, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S125–43. https://doi.org/10.2337/dc22-S009.

Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;2022(45):2753–86. https://doi.org/10.2337/dci22-0034.

Article  CAS  Google Scholar 

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol. 2019;74:e177–232. https://doi.org/10.1016/j.jacc.2019.03.010.

Article  PubMed  PubMed Central  Google Scholar 

Sociedad Española de Medicina Interna (SEMI). Actualización 2022 para el tratamiento de la DM2 del Grupo de Diabetes, Obesidad y Nutrición, https://www.fesemi.org/sites/default/files/documentos/grupos/noticias/algoritmo_semi_de_diabetes_2022_0.pdf; 2022. Accessed 13 Apr 2023.

Fernández Olmo MR, Cordero Fort A, Torres Llergo J, Marzal Martín D, Baquero Alonso M, Martínez Quesada M, et al. Selección de lo mejor del año en 2022 en riesgo vascular y rehabilitación cardiaca [Selection of the best of 2022 in vascular risk and cardiac rehabilitation]. REC: CardioClinics. 2023;58:S21–7. https://doi.org/10.1016/j.rccl.2022.10.002.

Article  Google Scholar 

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776–85. https://doi.org/10.1016/S2213-8587(19)30249-9.

Article  CAS  PubMed  Google Scholar 

Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell’Aversana S, Esposito I, et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41:3346–58. https://doi.org/10.1093/eurheartj/ehaa082.

Article  CAS  PubMed  Google Scholar 

Romera I, Rubio-de Santos M, Artola S, Suárez Fernández C, Conget I. GLP-1 RAs in Spain: a short narrative review of their use in real clinical practice. Adv Ther. 2023;40:1418–29. https://doi.org/10.1007/s12325-023-02442-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185. https://doi.org/10.1186/s12933-020-01154-w.

Article  PubMed  PubMed Central  Google Scholar 

Draznin B, Hirsch IB. Time to follow the evidence: glycemic control and cardiovascular benefits of new diabetes medications. Am J Med. 2021;134:420–2. https://doi.org/10.1016/j.amjmed.2020.12.012.

Article  PubMed  Google Scholar 

Nelson AJ, Ardissino M, Haynes K, Shambhu S, Eapen ZJ, McGuire DK, et al. Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. J Am Heart Assoc. 2021;10: e016835. https://doi.org/10.1161/JAHA.120.016835.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arnold SV, Tang F, Cooper A, Chen H, Gomes MB, Rathmann W, et al. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocr Disord. 2022;22:111. https://doi.org/10.1186/s12902-022-01026-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ministerio de Sanidad, Gobierno de España. Nomenclátor. https://www.sanidad.gob.es/profesionales/medicamentos.do; 2022. Accessed 22 Dec 2022.

Conget I, Mauricio D, Ortega R, Detournay B, CHADIG study investigators. Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain. BMJ Open. 2016;6:e010197. https://doi.org/10.1136/bmjopen-2015-010197.

Article  PubMed  PubMed Central  Google Scholar 

Mata-Cases M, Franch-Nadal J, Ortega E, Real J, Gratacòs M, Vlacho B, et al. Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area. Curr Med Res Opin. 2019;35:1735–44. https://doi.org/10.1080/03007995.2019.1618806.

Article  CAS  PubMed  Google Scholar 

Tofé S, Argüelles I, Mena E, Serra G, Codina M, Urgeles JR, et al. Real-world GLP-1 RA therapy in type 2 diabetes: a long-term effectiveness observational study. Endocrinol Diabetes Metab. 2019;2:e00051. https://doi.org/10.1002/edm2.51.

Article  CAS  PubMed  Google Scholar 

Norrbacka K, Sicras-Mainar A, Lebrec J, Artime E, Díaz S, Tofé-Povedano S, et al. Glucagon-like peptide 1 receptor agonists in type 2 diabetes mellitus: data from a real-world study in Spain. Diabetes Ther. 2021;12:1535–51. https://doi.org/10.1007/s13300-021-01039-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Obaya Rebollar JC, Miravet Jiménez S, Aranbarri Osoro I, Carramiñana Barrera FC, García Soidán FJ, Cebrián Cuenca AM. Management of patient profiles with type 2 diabetes mellitus in primary care in Spain: CONTROVERTI2 Program. SEMERGEN. 2022;48:23–37. https://doi.org/10.1016/j.semerg.2021.07.009.

Article  CAS  PubMed  Google Scholar 

Morillas C, Escalada J, Palomares R, Bellido D, Gómez-Peralta F, Pérez A. Treatment of type 2 diabetes by patient profile in the clinical practice of endocrinology in Spain: Delphi study results from the Think Twice Program. Diabetes Ther. 2019;10:1893–907. https://doi.org/10.1007/s13300-019-0671-x.

Article  PubMed  PubMed Central  Google Scholar 

López de la Torre M, Botana López M, Rozas Moreno P, Merino Torres J, Escalada San Martín J, Pérez Maraver M. Abordaje en la práctica clínica de endocrinólogos españoles de los aspectos cardiovasculares y renales del paciente con diabetes mellitus tipo 2: resultados de un estudio Delphi. Endocrinología Diabetes y Nutrición. 2021;68:111–2.

Google Scholar 

Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med. 2011;8:e1000393. https://doi.org/10.1371/journal.pmed.1000393.

Article  PubMed  PubMed Central  Google Scholar 

Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401–9. https://doi.org/10.1016/j.jclinepi.2013.12.002.

Article  PubMed  Google Scholar 

Birko S,